

Variant: *NM_001754.5(RUNX1):c.965del*
(*p.Leu321_Ser322insTer*)

Version: 1.0

CA2573157369 [↗](#)

1460663 (ClinVar) [↗](#)

Gene: RUNX1 (HGNC:861)

Condition: hereditary thrombocytopenia and hematologic cancer predisposition syndrome (MONDO:0011071)

Inheritance Mode: Autosomal dominant inheritance

UUID: ebe7d39f-0b88-4af9-a8d3-5c53ab3d0a9a

Approved on: 2024-09-10

Published on: 2024-09-10

HGVS expressions

NM_001754.5:c.965del

NM_001754.5(RUNX1):c.965del (p.Leu321_Ser322insTer)

NC_000021.9:g.34799303del

CM000683.2:g.34799303del

NC_000021.8:g.36171600del

CM000683.1:g.36171600del

NC_000021.7:g.35093470del

NG_011402.2:g.1190409del

ENST00000675419.1:c.965del

ENST00000300305.7:c.965del

ENST00000344691.8:c.884del

ENST00000399240.5:c.692del

ENST00000437180.5:c.965del

ENST00000482318.5:c.*555del

NM_001001890.2:c.884del

NM_001754.4:c.965del

NM_001001890.3:c.884del

Likely Pathogenic

Met criteria codes **3**

PM5_Supporting PM2_Supporting

PVS1_Strong

Not Met criteria codes **22**

BS2 BS1 BS4 BS3 BP4 BP3

BP1 BP2 BP5 BP7 PM1

PM3 BA1 PM4 PM6 PS1

PS2 PS3 PP1 PP2 PP3 PP4

Evidence Links **0**

Expert Panel

Myeloid Malignancy VCEP [↗](#)

Criteria Specification Information

[↗](#) **Criteria Specification:** ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

[↗](#) PDF







[↗](#) **Criteria Specification Approval History**

[↗](#) **Criteria Specifications for this VCEP**

















Myeloid Malignancy VCEP








NM_001754.5(RUNX1):c.965del (p.Ser322Ter) is a nonsense variant located downstream of c.98 in transcript NM_001754.4 (PM5_Supporting). It is not expected to undergo nonsense-mediated decay, and the resulting frameshift affects positions c.759-c.1440 as per VCEP specifications, which are critical for protein function (PVS1_Strong). This variant is completely absent from all population databases with at least 20x coverage for RUNX1 (PM2_Supporting). In summary, this variant meets criteria to be classified as likely pathogenic for hereditary thrombocytopenia and hematologic cancer predisposition syndrome based on the ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PVS1_strong, PM2_supporting, PM5_supporting.

Met criteria codes

PM5_Supporting			This variant is a nonsense/frameshift variants that is downstream of c.98 (PM5_Supporting).
PM2_Supporting			This variant is absent from gnomAD v.3.1.2 and gnomAD v2.1.1 which have at least 20x coverage for RUNX1 (PM2_supporting).
PVS1_Strong			This variant is not predicted to undergo NMD, and the truncated/alterd region is critical for protein function (nonsense c.917-c.1440 as per VCEP specifications) (PVS1_Strong).

Not Met criteria codes

BS2			This rule is not applicable for the MM.VCEP.
BS1			This variant is absent from gnomAD v.3.1.2 and gnomAD v2.1.1 which have at least 20x coverage for RUNX1 (PM2_supporting).
BS4			Segregation data for this variant has not been reported in literature.
BS3			In vitro or in vivo functional data has not been reported for this variant in the literature.
BP4			This variant does not have applicable in-silico data available.
BP3			This rule is not applicable for the MM.VCEP.
BP1			This rule is not applicable for the MM.VCEP.
BP2			This variant has not been observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
BP5			This rule is not applicable for the MM.VCEP.
BP7			This variant is not a synonymous or intronic variant.

PM1		✘	This variant does not affect any of the following amino acid residues, nor is it located within the RHD: R107, K110, A134, R162, R166, S167, R169, G170, K194, T196, D198, R201, R204 OR within residues 89-204.
PM3		✘	This rule is not applicable for the MM.VCEP.
BA1		✘	This variant is absent from gnomAD v.3.1.2 and gnomAD v2.1.1 which have at least 20x coverage for RUNX1 (PM2_supporting).
PM4		✘	This variant is not an in-frame deletion/insertion.
PM6		✘	De novo data for this variant has not been reported in literature.
PS1		✘	There has not yet been a missense change determined to be pathogenic at this amino acid residue.
PS2		✘	De novo data for this variant has not been reported in literature.
PS3		✘	In vitro or in vivo functional data has not been reported for this variant in the literature.
PP1		✘	Segregation data for this variant has not been reported in literature.
PP2		✘	This rule is not applicable for the MM.VCEP.
PP3		✘	This variant does not have applicable in-silico data available.
PP4		✘	This rule is not applicable for the MM.VCEP.

Curation History [↗](#)

Showing 1 to 1 of 1 rows

See Report	Preferred Variant Title	Classification	Condition	Published Date	Version	Criteria Specification	Gene
View	NM_001754.5(RUNX1):c.965del (p.Leu...	Likely Pathogenic	Hereditary Thrombocytopenia And Hematologic Cancer Predisposition Syndrome	2024-09-10	1.0	ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2	RUNX1

Showing 1 to 1 of 1 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.